Caladrius (CLBS) the former NeoStem engages in the development of proprietary cell therapy products.
Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications.
CLBS is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in an ongoing Phase 2 trial.
CLBS14, a CD34+ cell therapy intended as a treatment for coronary microvascular dysfunction, is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is specifically formulated for intramuscular administration for the treatment of lower extremity ischemia.
A phase 2 study of CLBS12 as a treatment for critical limb ischemia recently was initiated in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based on discussions with the Japanese regulatory authorities as provided for under Japan’s progressive regenerative medicine regulations.
Founded as NeoStem in 1980, CLBS is headquartered in Basking Ridge, NJ.
October 10, 2018
RegMed Investors’ (RMi) pre-open: I’m still waiting for a bounce-back in some sector equities
October 9, 2018
RegMed Investors’ (RMi) closing bell: seeing another bottom
October 8, 2018
RegMed Investors’ (RMi) closing bell: no snap, barely a crackle with a precipitous drop
October 5, 2018
RegMed Investors’ (RMi) closing bell: the headwinds crashed the upside at the mid-day, opposing its forward motion
October 2, 2018
RegMed Investors’ (RMi) closing bell: what’s today excuse for the downturn again?
October 1, 2018
RegMed Investors’ (RMi) closing bell: just when you thought value would return to the oversold
September 27, 2018
RegMed Investors’ (RMi) pre-open: the numbers are king but, they do bite
September 26, 2018
RegMed Investors’ (RMi) closing bell: kicking the can of equities down with alternating volatility
September 26, 2018
RegMed Investors’ (RMi) pre-open: share pricing is usually collateral damage in this market
September 25, 2018
RegMed Investors’ (RMi) closing bell: the sector is so fickle
35 companies, 1 interpreter!
Insight, foresight and recommendation
Caladrius (CLBS) -- Started 2018 at $3.70, saw a high of $4.30 dropped on February 1 to $4.12 and has been dribbling between 2/7 to 2/16 at $3.93. 3/6 – a surprise, Caladrius Biosciences (CLBS) acquired an exclusive license to a late stage CD34+ Cell Therapy Program for the treatment of Refractory Angina from Shire plc (SHP.L) (SHPG). CLBS had closed at $5.03 and was up +$1.58 slipping to $0.55 or +11.13% (was +31.41%) …
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.